Peter S. Kim

Peter S. Kim, Ph.D. joined 5AM Ventures in 2014 and is currently a Venture Advisor. He is the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine, an Institute Scholar of Stanford ChEM-H, and Lead Investigator for the Infectious Disease Initiative at the Chan Zuckerberg Biohub. He is an elected member of the National Academy of Sciences, the National Academy of Medicine (formerly the Institute of Medicine), the National Academy of Engineering and the American Academy of Arts and Sciences. He serves on several academic advisory boards including the Medical Advisory Board of the Howard Hughes Medical Institute (HHMI). Well-known for discovering how proteins cause viral membranes to fuse with cells, he has designed compounds to stop membrane fusion by the AIDS virus and pioneered efforts to develop an HIV vaccine. Dr. Kim was President of Merck Research Laboratories (2003- 2013) during which time the company gained approval for more than 20 new medicines and vaccines, including JANUVIA, GARDASIL, ISENTRESS and ZOSTAVAX. He also oversaw the biomarker-based development of KEYTRUDA. Previously, Dr. Kim was a Professor of Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute and Investigator at the Howard Hughes Medical Institute. Dr. Kim received his A.B. in Chemistry from Cornell University and his Ph.D. in Biochemistry from Stanford University. Dr. Kim is based in the San Francisco, CA office.